Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
August 2025
The global pharmaceutical blister packaging market size is calculated at USD 23.41 billion in 2025 and is forecasted to reach around USD 45.46 billion by 2034, accelerating at a CAGR of 7.65% from 2025 to 2034. The North America market size surpassed USD 6.96 billion in 2024 and is expanding at a CAGR of 7.81% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global pharmaceutical blister packaging market size accounted for USD 21.75 billion in 2024 and is predicted to increase from USD 23.41 billion in 2025 to approximately USD 45.46 billion by 2034, expanding at a CAGR of 7.65% from 2025 to 2034. Growth in e-pharmacies and demand for tamper-evident packaging solutions, innovation in cold form foil technology for improved drug protection, and generic drug manufacturing expansion are driving the growth of the pharmaceutical blister packaging market.
Artificial intelligence (AI) improves packaging processes for blister packs and vials, automating quality control inspections. Real-time monitoring through AI maintains reliable, consistent, and effective production, ensuring higher quality. AI can play an important role in packaging manufacturing quality control. It can scan packaging products at many stages of the manufacturing process and detect defects at a micro-level that can be invisible to the human eye, whereas traditional quality checks are labor-intensive and can miss subtle defects.
AI techniques can analyze large-scale biomedical data to identify existing drugs that may have therapeutic potential for different diseases. By repurposing approved drugs for new indications, AI accelerates the drug discovery process and reduces costs. AI helps in packaging design, including in-text effects, turns initial sketches into packaging designs, generates design ideas from text prompts, simulation testing, refines and perfects designs, creates prompts, and creates a brand kit.
The U.S. pharmaceutical blister packaging market size was exhibited at USD 4.87 billion in 2024 and is projected to be worth around USD 10.42 billion by 2034, growing at a CAGR of 7.90% from 2025 to 2034.
North America held a significant share of 32% in the pharmaceutical blister packaging market in 2024. High demand for tamper-evident packaging solutions, growth in e-pharmacies, innovation in cold form foil technology for improved drug protection, expansion of generic drug manufacturing, and rising prevalence of chronic diseases contribute to the growth of the pharmaceutical blister packaging market in the North American region.
Asia Pacific is anticipated to grow at the fastest rate of CAGR 8.90% in the market during the forecast period. The integration of IoT, automation, and digitalization leads to reducing costs and streamlining operations, suitable governmental policies, a shift towards high performance and sustainable solutions, and rapid technological innovation contributing to the growth of the pharmaceutical blister packaging market.
Pharmaceutical blister packaging is a form of tamper-evident packaging where an individual pushes individually sealed tablets through the foil to take the medication. This form of packaging can also help the individual recall if the previous dose was taken. A blister pack is any of many types of pre-formed plastic packaging used for small consumer goods, foods, and pharmaceuticals. Blister packs are generally used as unit-dose packaging for pharmaceutical tablets, capsules, or lozenges. It can provide barrier protection for shelf-life needs and a degree of tamper resistance.
Blister packs can protect from environmental factors; they safeguard drugs from air, moisture, and contamination. Each blister corresponds to a single dose, making it easier for patients to track their medication intake. Blister packaging production will be far more intelligent, flexible, and automated in the future.
| Report Coverage | Details |
| Market Size by 2034 | USD 45.46 Billion |
| Market Size in 2025 | USD 23.41 Billion |
| Market Size in 2024 | USD 21.75 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 7.65% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Blister Type, Material Composition, Drug Form, Technology Used, Functionality, Packaging Format, Distribution Channel, End-user, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Innovation in cold-form foil technology
Innovation in cold-form foil technology helps improve drug protection. It offers protection against light, moisture, and oxygen, thereby ensuring the medication's integrity and stability. Innovations in blister packaging materials for pharmaceutical products are making it eco-friendlier and more efficient than ever. The cold-forming blister packaging technique uses thin sheets of laminate film containing aluminium. To create blister packs with cold forming, the blister machine generally uses a stamp to force the sheets into a form, allowing the aluminum-based film to stretch and retain the mold shape after the stamp is removed.
Complexities in blister packaging
Complexities in blister packaging may include poor barrier against moisture ingress and oxygen ingress. In the case of blister packaging, the PVC sheet does not contain any plasticizer and is sometimes referred to as Rigid PVC or RPVC. Normally, blister packaging is formed using durable and long-lasting materials. But sometimes, the packaging breaks after the sealing, bringing about product damage, contamination, and customer dissatisfaction. Breakage may be due to poor-quality plastic polymers and backing materials.
Increasing investment in research and development (R&D)
Research and development (R&D) can help our ideas or business become more attractive to investors and other companies looking to expand. Investing in R&D allows us to broaden our product or service offer, reducing reliance on a single product. This diversification can help us to adapt quickly to market changes and stay competitive even in tough economic times. The benefits of increased investment include tax benefits, a better option than savings accounts, growth potential, market performance, combining passion with financial growth, diversifying portfolio, planning for retirement, providing regular income, and growing our wealth.
The thermoformed blister segment dominated the pharmaceutical blister packaging market with the largest market share of approximately 65% in 2024. Thermoforming benefits include customization for industry-specific needs, industry versatility, versatility in parts, focus on sustainability, product durability, creating lightweight products, a wide range of material options, reduced lead times across industries, design flexibility, and thermoforming is cost-effective.
The paper-based blisters segment is expected to grow fastest rate of 12.50% in the market during the forecast period of 2025 to 2034. Using paper-based blister packs benefits the environment and improves branding. It also enhances packaging productivity. This makes it easier for consumers to know how much medication to take at one time. Another advantage of blister packaging is convenience. Blister packs are generally lighter, smaller, and less unwieldy than a typical pill bottle. Consequently, they are easy to store and easy to transport.
The plastic-based films segment peaked with the largest share of 55% in the market in 2024. Plastic used in blister packaging is comprised of PET (polyethylene terephthalate) or PVC (polyvinyl chloride) plastic packaging. The rugged material used for blister packs makes them ideal for a wide range of applications like pharmaceuticals, electronic equipment, or toy products.
The multi-layer laminates segment is projected to experience the highest growth rate of 10.80% in the pharmaceutical blister packaging market between 2025 and 2034. Multi-layer laminates in blister packs are flexible films that prevent water, oxygen, light, and other elements from entering or exiting a product’s packaging. Multi-layer laminates engineered for high moisture and oxygen barrier performance.
The solid oral dosage form segment held the largest share of 72% in 2024. Among the many packaging solutions available, blister packaging has emerged as the gold standard for solid oral dosage forms, accounting for over 70% of unit dose packaging in developed markets. Blister packaging consists of a thermoformed plastic cavity sealed with an aluminum foil or paper cover.
The transdermal patches (unit-dose) segment is set to experience the fastest rate of 9.60% in the pharmaceutical blister packaging market growth from 2025 to 2034. As compared to traditional dosage forms, transdermal patches offer key benefits, including steady, controlled medication release with fewer side effects and more consistent effects. A non-invasive, pain-free option for those who have trouble with pills or injections. Easy to use and discreet, making them ideal for many patients.
The thermoforming segment held the largest share of the market at around 58% in 2024. Thermoforming stands out for its remarkable cost-effectiveness in many ways. It boasts low tooling costs, making it accessible to businesses of all sizes. In addition, thermoforming is highly material-efficient, reducing waste and contributing to sustainability.
The anti-counterfeit segment is anticipated to grow with the highest CAGR of 11.30% in the market during the studied years. Anti-counterfeit technology’s main goal is to ensure that only genuine products reach the market. It helps businesses to track their goods, prove authenticity, and stop fake items from spreading.
The standard blister packaging segment held the largest share of the market at around 60% in 2024. The standard blister packaging benefits include cost-effectiveness, brand-visibility & marketing, extended shelf life, security, temper evidence, improved consumer convenience, and improved product protection. This makes it easy to consumers to know how much medication to take at one time.
The environmentally sustainable packs segment is anticipated to grow with the highest CAGR of 13.40% in the market during the studied years. Environmentally friendly blister packaging solutions addresses the concerns by reducing waste, lowering carbon emissions, and promoting recyclability.
The multi-cavity/strip packs segment registered its dominance over the pharmaceutical blister packaging market with a share of 50% in 2024. Multi-cavity blanking allows companies to produce more parts at one time. Inferior equipment can generate burrs and cracks along the edges of the blank. Multi-cavity molding is a process that allows multiple identical parts to be produced in a single cycle, reducing costs, waste, and time.
The blister wallets and cards segment is predicted to witness significant growth of 9.20% in the market over the forecast period. Blister wallets are excellent at protecting medications from environmental factors like light, air, and moisture. Each dose is securely encased in its own blister, minimizing exposure to conditions that can degrade the medication before it is used.
The direct-to-pharma segment led the market with a share of 70% in 2024. Direct to the pharma distribution channel, manufacturers can transact directly with pharmacies to connect with the final consumer. It refers to the marketing and advertising of pharmaceutical products directly to consumers as patients, as opposed to specifically targeting health professionals.
The online pharmacies segment is predicted to witness significant growth of 14.10% the market over the forecast period. An online pharmacy platform is an effective model that helps to reach more customers, helps in better inventory management, offers better purchasing margins, competitive and reduced prices for medicines, and offers options for generic medicines.
The pharma manufacturers segment enjoyed a prominent position in the market share of 68% in 2024. The benefits of pharma manufacturers include selective supplier partnerships, reduced costs, reduced risk, quality control, product range, on-time delivery, investment, inventory management, increased efficiency, healthcare advancement, established brand & reputation, cost-effective production, broadening product line, market expansion opportunities, cost savings, focus on core competencies, faster market entry, advanced technology & expertise, scalability & flexibility, and regulatory compliance.
The clinical trial supply providers segment is expected to grow fastest rate of 10.50% in the market during the forecast period of 2025 to 2034. Well-designed and well-performed clinical trials provide benefits while allowing us to help others by contributing to knowledge about new treatments or procedures.
By Blister Type
By Material Composition
By Drug Form
By Technology Used
By Functionality
By Packaging Format
By Distribution Channel (for DTC or B2B customized packs)
By End-user
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
August 2025
April 2025
February 2025
September 2024